Revolutionary device Proven performance

Study design

- Prospective, multi-center
- 120 limbs at 12 sites
- Lesion length ≥ 5 cm
- Primary patency by duplex (PSVR < 2.5)
- Independent Core Lab vessel sizing

Lesion characteristics

- Average lesion length 19 cm
- 56% Chronic Total Occlusion

Results

- One-year primary patency 73 percent (*Figure 1*)
- Patency independent of device diameter (5 mm device same as 6 mm device) and lesion length
- Primary patency is improved ($p < 0.05$) when IFU sizing not exceeded (*Figure 2*)

One-year results for the Gore VIPER Clinical Study*

Principle Investigator: Richard Saxon, MD

The first controlled, multi-center, prospective study evaluating GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface and Contoured Proximal Edge



Figure 1. One-year device patency



Figure 2. Primary patency versus oversizing at the proximal edge

* Saxon RR, Chervu A, Jones PA, *et al.* Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) Trial. *Journal of Vascular & Interventional Radiology* 2013;24(2):165-173.

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com

GORE
VIPER
CLINICAL STUDY